Patients treated within your trust

Oliver Caswell made this Freedom of Information request to Grampian Health Board as part of a batch sent to 213 authorities

Automatic anti-spam measures are in place for this older request. Please let us know if a further response is expected or if you are having trouble responding.

The request was partially successful.

Dear Grampian Health Board,

The following questions with regards to patients treated in your trust are being asked for on behalf of Novartis.

1) In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?

2) Of these five, how many of each received the following products:

- Adalimumab (Humira)
- Adalimumab Biosimilar
- Etanercept (Enbrel)
- Etanercept Biosimilar
- Infliximab (Remicade)
- Infliximab biosimilar
- Golimumab (Simponi)
- Tofacitinib (Xeljanz)
- Ustekinumab (Stelara)
- Vedolizumab (Entyvio)
- Filgotinib (Jyseleca)
- Abatacept (Orencia)
- Baricitinib (Olumiant)
- Certolizumab Pegol (Cimzia)
- Rituximab (MabThera)
- Rituximab Biosimilar
- Tocilizumab (RoActemra)
- Sarilumab (Kevzara)
- Apremilast (Otezla)
- Secukinumab (Cosentyx)
- Isekizumab (Taltz)
- Guselkumab (Tremfya)
- Brodalumab (Kyntheum)
- Risankizumab (Skyrizi)
- Tildrakizumab (Ilumetri)
- Upadacitinib (Rinvoq)
- Bimekizumab (Bimzelx)

3) Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).

4) Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?

- AxSPA
- PsA
- PsO

Thank you for taking the time to answer these questions, and I look forward to your response.

Yours faithfully,

Oliver Caswell

GRAM Foi, Grampian Health Board

Dear Mr Caswell,

 

Freedom of Information (Scotland) Act 2002

 

Thank you for your email dated 5 July 2022, requesting information
regarding drug usage. We have recorded this request and are currently
processing it in accordance with the Freedom of Information (Scotland) Act
2002.

 

A response to your request for information is due by 3 August 2022. Please
allow for delivery time.

 

We will contact you again in due course.

 

Best wishes,

 

Roohi

 

Roohi Bains

Information Governance Manager & Deputy DPO

Information Governance Team

 

NHS Grampian

Rosehill House

Cornhill Road

Aberdeen

AB25 2ZG

 

Phone: 01224 551319

[1][NHS Grampian request email]

 

 

 

 

--------------------------------------------------------------------------------------------------------------------------------------------------------
This email is intended for the named recipient only. If you have received
it by mistake,
please (i) contact the sender by email reply; (ii) delete the email from
your system; .
and (iii) do not copy the email or disclose its contents to anyone.

--------------------------------------------------------------------------------------------------------------------------------------------------------

References

Visible links
1. mailto:[NHS Grampian request email]

GRAM Foi, Grampian Health Board

1 Attachment

Dear Mr Caswell

 

Please find attached response to your request.

 

I apologise for the slight delay.

 

Regards

 

Chris

 

Chris Morrice

Senior Information Governance Officer

NHS Grampian

Rosehill House

ARI

AB25 2ZG

 

Email: [email address]

 

 

 

--------------------------------------------------------------------------------------------------------------------------------------------------------
This email is intended for the named recipient only. If you have received
it by mistake,
please (i) contact the sender by email reply; (ii) delete the email from
your system; .
and (iii) do not copy the email or disclose its contents to anyone.

--------------------------------------------------------------------------------------------------------------------------------------------------------